Adagene Inc.
Adagene (NASDAQ: ADAG) announced the clinical development of ADG138, a dual-masked HER2-CD3 T-cell engager using SAFEbody technology. The company expects to begin dosing patients this quarter. Adagene also discussed potential autoimmune applications, partnerships with Third Arc Bio, Sanofi, and Exelixis, and upcoming catalysts, including Phase II data for muzastotug in 2027.
Tam Man Kin (Chief Financial Officer) purchased 2,000 shares of Adagene Inc. (ADAG) at $3.00 on 2026-09-23.
Luo Peter (Chief Executive Officer) purchased 20,290 shares of Adagene Inc. (ADAG) at $3.15 on 2026-09-16.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning ADAG (Adagene Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent ADAG coverage spans financial news, insider activity and technology.
In the last 30 days, ADAG insiders filed 2 SEC Form 4 transactions — 2 purchases ($70K) and no sales. The most active reporter was Luo Peter, Chief Executive Officer, with 1 filing.
The IND clearance and upcoming trial initiation represent a material milestone for Adagene's pipeline.
Small insider buy signals modest confidence but limited price impact.
Minor insider purchase; limited price impact.
This is a routine insider buy disclosure with limited incremental signal, since it is a small, non-10b5-1 purchase and provides no new company fundamentals.
The update strengthens the clinical narrative for muzastotug as a CTLA-4 SAFEbody backbone, while extending cash runway into late 2028.
AlphAI scores every news story that mentions ADAG with an AI model for sentiment and relevance, and aggregates insider trades from Adagene Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Adagene (NASDAQ: ADAG) announced the clinical development of ADG138, a dual-masked HER2-CD3 T-cell engager using SAFEbody technology. The company expects to begin dosing patients this quarter. Adagene also discussed potential autoimmune applications, partnerships with Third Arc Bio, Sanofi, and Exelixis, and upcoming catalysts, including Phase II data for muzastotug in 2027.
2 min readTam Man Kin (Chief Financial Officer) purchased 2,000 shares of Adagene Inc. (ADAG) at $3.00 on 2026-09-23.
1 min readLuo Peter (Chief Executive Officer) purchased 20,290 shares of Adagene Inc. (ADAG) at $3.15 on 2026-09-16.
1 min readDO CUONG V purchased 2,000 shares of Adagene Inc. (ADAG) at $3.75 on 2026-08-14.
1 min readAdagene (Nasdaq: ADAG) reported six months ended June 30, 2026 results and clinical updates on muzastotug (ADG126). Cash and equivalents were $127.9 million, extending runway into late 2028. Phase 1b/2 data in MSS CRC with pembrolizumab showed ORR 13% to 31% and median PFS 4.8 to 6.7 months, with Phase 2 results expected in 1H 2027.
6 min readLuo Peter (Chief Executive Officer) purchased 23,245 shares of Adagene Inc. (ADAG) at an average of $3.65 ($3.65–$3.65) across 2 trades over 2026-08-04 to 2026-08-05.
2 min readAdagene Inc. has appointed Peter Lebowitz, MD, Ph.D. to its Scientific and Strategic Advisory Board. Dr. Lebowitz, formerly Global Head of Oncology R&D at Johnson & Johnson, brings extensive experience in drug development and is recognized for his contributions to advancing novel therapies from discovery to commercialization. His expertise will guide the continued clinical development of Adagene's lead program, ADG126, a masked anti-CTLA-4 SAFEbody, particularly in strategies for registration-enabling studies and exploring future combination approaches.
3 min readAdagene Inc. announced unaudited cash and cash equivalents of $74.5 million as of December 31, 2025, providing a sufficient financial runway into late 2027. The company highlighted key accomplishments from 2025, including progress in its muzastotug clinical trials and strategic collaborations with Sanofi, Third Arc Bio, Exelixis, and ConjugateBio. Adagene also outlined its 2026 objectives, focusing on further clinical data updates for muzastotug in various cancer indications and securing additional partnerships.
3 min readAdagene Inc. (ADAG) announced that the FDA granted Fast Track designation to its lead clinical-stage immuno-oncology candidate, muzastotug (ADG126), in combination with Merck’s Keytruda for treating adult patients with microsatellite-stable metastatic colorectal cancer. This designation aims to facilitate drug development and expedite review for serious diseases with unmet medical needs. ADAG shares surged 13.8% following the announcement, reflecting positive investor sentiment.
3 min readAdagene Inc. shares rose significantly after the FDA granted fast track designation to its differentiated anti-CD137 agonist antibody, ADG106, for advanced solid tumors and non-Hodgkin lymphoma. This designation aims to accelerate the development and review of treatments for serious conditions with unmet medical needs. ADG106 is currently in Phase I clinical trials in both the U.S. and China.
4 min read
